Wilms Tumor Stages and Survival Rates: What Every Parent Should Know

Hearing the words "your child has cancer" is every parent's worst fear. But when that cancer is Wilms tumor, there is an important reason for hope. Wilms tumor is one of the most treatable childhood cancers, with overall survival rates exceeding 90%, and even higher cure rates for children diagnosed at an early stage with favourable tumor features.

While the journey through treatment can be challenging, understanding the stages of Wilms tumor and what they mean for prognosis can help families feel more informed and prepared. This guide explains the staging system, survival rates, and what parents should know to better navigate their child's treatment journey.

What Is Wilms Tumor?

Wilms tumor, also called nephroblastoma, is a cancer that develops in the kidneys and is by far the most common type of kidney cancer in children. It's named after Max Wilms, the German surgeon who first described it in the late 1800s. The tumor arises from immature kidney cells that failed to fully develop before birth, which is part of why it overwhelmingly affects young children rather than adults.

Most children are diagnosed between ages of 1 and 5, with the average age at diagnosis around 3 to 3.5 years. It accounts for roughly 6% to 7% of all childhood cancers, and its incidence has remained relatively stable over the past two decades, at approximately 5.7 cases per million children. The condition is slightly more common in girls than boys.

In most cases, Wilms tumor is discovered when a parent or paediatrician notices an abdominal swelling or a firm lump in the belly, often during a bath or routine checkup. It's typically painless, which is part of why it can grow to a noticeable size before being found. Other possible symptoms include blood in the urine, high blood pressure, fever, loss of appetite, or general fatigue, though many children show no symptoms at all beyond the abdominal mass.

How Wilms Tumor Is Staged

Staging is the process doctors use to describe how far a cancer has spread, and it's one of the two biggest factors - along with histology, discussed below - that determine both treatment and prognosis. Oncologists primarily use the staging system, which divides Wilms tumor into five stages using Roman numerals I through V. Staging is based on a combination of imaging results and, critically, what is found during and after surgery.

The Five Stages of Wilms Tumor

A few clarifications that matter to parents trying to make sense of a stage assigned to their own child: stage is determined largely by what surgeons find, not just what shows up on a scan beforehand. This is why the final stage is sometimes different from what doctors initially expected based on imaging alone. It's also why complete surgical removal, done carefully to avoid tumor spillage, is such an important part of treatment - spillage during surgery can shift a tumor from stage II into stage III, since it raises the risk of local recurrence.

Why Histology Matters in Predicting Outcomes

Stage tells doctors how far the cancer has spread. Histology tells them how aggressive the cancer cells look under a microscope - and it matters just as much, sometimes more, than stage itself.

• Favourable histology (FH) describes tumor cells that, despite being cancerous, don't show severe abnormalities in their structure. This is the case in roughly 90% of Wilms tumors, and it's associated with a markedly better prognosis at every stage.
• Anaplastic (unfavourable) histology describes tumor cells with significant abnormalities, including enlarged, distorted nuclei and abnormal cell division. Anaplasia can be focal (limited to a small area) or diffuse (spread throughout the tumor), with diffuse anaplasia carrying a meaningfully worse prognosis. Anaplastic tumors are less common but require more intensive treatment.

Doctors also look for other risk features under the microscope, including loss of heterozygosity (LOH) at chromosome regions 1p and 16q, which has been shown to be associated with an increased risk of relapse and death, even within the same stage. This is one reason two children with a "stage II" diagnosis can sometimes receive different treatment intensities - their tumor biology isn't identical, even if their stage number is.

Speak with a Pediatric Oncology Expert

Need expert guidance on your child's diagnosis or treatment plan? Connect with leading pediatric oncology specialists.

Consult with Specialist

Talk to Expert

Survival Rates by Stage

Wilms tumor survival is often reported as either a 4-year or 5-year rate, and it's usually broken down separately for favourable histology and anaplastic histology, since the difference in outcome is significant. Overall, taking all stages together, the 5-year relative survival rate for children with Wilms tumor is approximately 92% to 96%, making it one of the more curable solid tumors in pediatric oncology.

4-Year Survival Rates by Stage and Histology

Individual outcomes vary based on age, tumor biology, and response to treatment.

A few things stand out in this table that are worth explaining directly to parents:

• Stage IV favourable-histology Wilms tumor still has excellent outcomes: Although stage IV means the cancer has spread, children with favourable histology often achieve 85%-90% four-year survival because the tumor responds well to chemotherapy, surgery, and radiation.
• Histology can be more important than stage: A child with stage I anaplastic Wilms tumor may have a poorer prognosis than one with stage III favourable-histology disease, highlighting why both stage and tumor biology are essential in predicting outcomes.
• Stage V (bilateral) disease requires a different approach: When both kidneys are affected, treatment focuses on eliminating the cancer while preserving as much kidney function as possible, often making therapy more individualised and longer in duration.

Age, Race, and Other Factors That Influence Outcomes

Recent large-scale data from government registries have highlighted some additional patterns that affect prognosis beyond stage and histology alone:

• Age at diagnosis matters: Children under 2 years old at diagnosis generally have a more favourable prognosis than older children. Adolescents diagnosed between ages 10 and 19, while rare, have shown somewhat lower survival than younger children with the disease.
• Stage at diagnosis strongly predicts survival: Children with regional or distant-stage disease at diagnosis have a significantly higher risk than those with localised disease.
• Disparities exist in outcomes: Population data have shown that non-Hispanic Black patients have had somewhat lower survival rates than non-Hispanic White patients, and children from non-metropolitan counties have shown lower survival than those from metropolitan areas - differences researchers attribute to a mix of access-to-care factors, timing of diagnosis, and the need for continued research into equitable treatment delivery.
• Treatment era matters. Children diagnosed and treated more recently have shown meaningfully better survival than those treated in earlier decades, reflecting steady improvements in chemotherapy regimens, surgical technique, and risk-stratified treatment protocols developed through large cooperative clinical trials.

How Wilms Tumor Is Treated

Treatment is tailored to the stage, histology, and the results of specific genetic tests on the tumor tissue. In general terms:

This last point deserves emphasis: the reason Wilms tumor treatment has become so effective is decades of large, carefully designed cooperative trials that have refined exactly how much treatment each risk group needs - no more, no less. This "risk-adapted" approach means many children with low-risk disease now receive less intensive treatment than children did a generation ago, without sacrificing cure rates, which also reduces long-term side effects.

What Survival Statistics Do - and Don't - Tell You

Survival rates are based on large groups of children treated in the past, often four or more years ago. They tell you what portion of children in a similar situation were alive at a certain point after diagnosis; they cannot tell you what will happen to any individual child. Two children with the same stage and histology can still have different outcomes based on how their particular tumor responds to treatment, their overall health, and other individual factors that statistics can't capture.

It's also worth remembering that treatment keeps improving. A 5-year survival rate reported today is often based on children treated several years ago, meaning outcomes for children diagnosed now may be even better than current published statistics suggest, as newer refinements in chemotherapy dosing and risk stratification continue to be adopted.

If your child has been diagnosed with Wilms tumor, the single most useful thing you can do with statistics like these is bring them to your child's oncology team and ask how they apply specifically to your child's stage, histology, and overall clinical picture. Numbers on a page are a starting point for that conversation, not a replacement for it.

Long-Term Outlook and Follow-Up Care

Because survival rates for Wilms tumor are so high, a growing focus in pediatric oncology has shifted toward long-term follow-up - monitoring survivors for potential late effects of treatment, such as effects on kidney function (particularly important given the disease's location), heart function from certain chemotherapy agents, and, in children who received radiation, effects on growth or secondary cancer risk later in life. Most survivors go on to live full, healthy lives, but ongoing follow-up care with a pediatric oncologist or a survivorship program is an important part of the picture even after treatment ends successfully.

How MediGence Can Support Your Family

Navigating a childhood cancer diagnosis involves much more than treatment alone. Families often need help finding experienced pediatric oncology specialists, understanding treatment options, arranging second opinions, and accessing advanced care when required.

MediGence supports families throughout this journey by connecting them with leading children's cancer hospitals and specialists worldwide. From helping you explore personalised treatment options and facilitating online consultations to coordinating international medical travel and providing dedicated case management, MediGence aims to make accessing world-class care simpler and less overwhelming.

While every child's treatment plan should be guided by their oncology team, having the right support and trusted medical guidance can help families make informed decisions with greater confidence.